OBJECTIVES: The refusal of blood products makes open-heart surgery in Jehovah's witnesses (JW) an ethical challenge. We demonstrate how patient blood management strategies lead to excellent surgical outcomes. METHODS: From 2003 to 2008, 16 JW underwent cardiac surgery at our institution. Only senior surgeons performed coronary revascularization (n=6), valve (n=6), combined (n=1) and aortic surgery (n=3) of which two patients presented with acute type-A dissection. Off-pump surgery remained the method of choice for patients requiring a bypass procedure (n=5). Preoperative hematocrit (Hk) and hemoglobin (Hb) were 42.8±4.7% and 14.5±2 g/dl. In three patients with an Hb<12 g/dl, preoperative hematological stimulating treatment was implemented. RESULTS: All patients survived, no major complications occurred and no blood transfusion was administered. The Cell Saver® system (transfused volume: 474±101 ml) and synthetic plasma substitutes [Ringer's Lactate: 873±367 ml and hydroxyethyl starch (HES) 6%: 700±388 ml] were used routinely as well as hemostaticas, such as bone wax, and fibrin glue. The decrease of Hk and Hb appeared to be the lowest after off-pump surgery when compared to all other procedures requiring cardiopulmonary bypass (CPB) (25±9% vs. 33±6%; P=0.01 and 22±9% vs. 31±6%; P=0.04). Similarly, the decrease of platelets was significantly lower (20±12% vs. 43±14%; P=0.01). In the follow-up period (52±34 months), one patient died due to a non-cardiac reason, whereas all others were alive, in good clinical condition and did not have major adverse cardiac events (MACE) or recurrent symptoms requiring re-intervention. CONCLUSION: Patient blood management leads to excellent short- and long-term outcomes in JW. Combined efforts in regard to preoperative hematological parameter optimization, effective volume management and meticulous surgical techniques make this possible but raise the cautionary note why this is only possible in JW patients.
OBJECTIVES: The refusal of blood products makes open-heart surgery in Jehovah's witnesses (JW) an ethical challenge. We demonstrate how patient blood management strategies lead to excellent surgical outcomes. METHODS: From 2003 to 2008, 16 JW underwent cardiac surgery at our institution. Only senior surgeons performed coronary revascularization (n=6), valve (n=6), combined (n=1) and aortic surgery (n=3) of which two patients presented with acute type-A dissection. Off-pump surgery remained the method of choice for patients requiring a bypass procedure (n=5). Preoperative hematocrit (Hk) and hemoglobin (Hb) were 42.8±4.7% and 14.5±2 g/dl. In three patients with an Hb<12 g/dl, preoperative hematological stimulating treatment was implemented. RESULTS: All patients survived, no major complications occurred and no blood transfusion was administered. The Cell Saver® system (transfused volume: 474±101 ml) and synthetic plasma substitutes [Ringer's Lactate: 873±367 ml and hydroxyethyl starch (HES) 6%: 700±388 ml] were used routinely as well as hemostaticas, such as bone wax, and fibrin glue. The decrease of Hk and Hb appeared to be the lowest after off-pump surgery when compared to all other procedures requiring cardiopulmonary bypass (CPB) (25±9% vs. 33±6%; P=0.01 and 22±9% vs. 31±6%; P=0.04). Similarly, the decrease of platelets was significantly lower (20±12% vs. 43±14%; P=0.01). In the follow-up period (52±34 months), one patient died due to a non-cardiac reason, whereas all others were alive, in good clinical condition and did not have major adverse cardiac events (MACE) or recurrent symptoms requiring re-intervention. CONCLUSION:Patient blood management leads to excellent short- and long-term outcomes in JW. Combined efforts in regard to preoperative hematological parameter optimization, effective volume management and meticulous surgical techniques make this possible but raise the cautionary note why this is only possible in JW patients.
Authors: Steven M Frank; Elizabeth C Wick; Amy E Dezern; Paul M Ness; Jack O Wasey; Andrew C Pippa; Elizabeth Dackiw; Linda M S Resar Journal: Transfusion Date: 2014-06-18 Impact factor: 3.157
Authors: Claude D Vaislic; Nicolas Dalibon; Oliver Ponzio; Maguette Ba; Eric Jugan; Franck Lagneau; Philippe Abbas; Yves Olliver; Didier Gaillard; Francois Baget; Michel Sportiche; Antoine Chedid; Georges Chaoul; Philippe Maribas; Christiane Dupuy; Bruno Robine; Nicolas Kasanin; Herve Michon; Jean-Michel Ruat; Michel Habis; Touhami Bouharaoua Journal: J Cardiothorac Surg Date: 2012-09-27 Impact factor: 1.637
Authors: Patrick Meybohm; Dania Patricia Fischer; Christof Geisen; Markus Matthias Müller; Christian Friedrich Weber; Eva Herrmann; Björn Steffen; Erhard Seifried; Kai Zacharowski Journal: BMC Health Serv Res Date: 2014-11-19 Impact factor: 2.655
Authors: Brian A Bruckner; Lance N Blau; Limael Rodriguez; Erik E Suarez; Uy Q Ngo; Michael J Reardon; Matthias Loebe Journal: J Cardiothorac Surg Date: 2014-08-02 Impact factor: 1.637
Authors: Sotirios Marinakis; Philippe Van der Linden; Redente Tortora; Jacques Massaut; Charalampos Pierrakos; Pierre Wauthy Journal: J Cardiothorac Surg Date: 2016-04-14 Impact factor: 1.637